Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Ionis Pharmaceuticals, Inc. operates as a biotechnology company. The Company researches in RNA-targeted drug discovery and development that focuses on drugs for patients who have unmet medical needs. Ionis Pharmaceuticals serves customers in the United States.
Website: ionispharma.com



Growth: Good revenue growth rate 17.2%, there is slowdown compared to average historical growth rates 22.6%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -11.9%

Profitability: LTM EBITDA margin is negative, -26.5%. On average the margin is improving steadily. Gross margin is high, +98.5%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.23 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -8.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 217.5% higher than minimum and 2.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.3x by EV / Sales multiple , the company can be 89.1% overvalued

Insiders: For the last 3 months insiders sold company shares on $38.3 mln (-0.339% of cap.)

Key Financials (Download financials)

Ticker: IONS
Share price, USD:  (0.0%)81
year average price 52.24  


year start price 31.40 2025-02-07

min close price 25.51 2025-04-08

max close price 82.73 2025-11-28

current price 81.00 2026-02-07
Common stocks: 141 798 003

Dividend Yield:  0.0%
EV / Sales: 11.7x
Margin (EBITDA LTM / Revenue): -26.5%
Fundamental value created in LTM:
Market Cap ($m): 11 486
Net Debt ($m): -150
EV (Enterprise Value): 11 336
Price to Book: 18.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-22zacks.com

Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema

2026-01-13seekingalpha.com

Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-11-13seekingalpha.com

Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2025 Healthcare Conference Transcript

2025-11-13businesswire.com

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

2025-11-10seekingalpha.com

Ionis: Near-Term Launches With Blockbuster Potential Boosts Upside Despite Stock Rally

2025-11-10benzinga.com

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug

2025-11-08businesswire.com

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

2025-11-04seekingalpha.com

Ionis: What Upside Is Left After Shares Rocketed Higher Following Positive Trial Data?

2025-10-29zacks.com

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates

2025-10-23businesswire.com

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-10-28 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015
fillingDate 2025-10-28 2025-07-30 2024-11-06 2024-08-01 2024-03-31 2023-11-02 2023-08-09 2023-05-03 2022-11-09
acceptedDate 2025-10-29 03:06:01 2025-07-30 15:56:18 2025-02-19 16:06:39 2024-11-06 16:06:54 2024-08-01 16:57:19 2024-03-29 20:00:00 2024-02-21 16:38:27 2023-11-02 14:43:27 2023-08-09 13:50:14 2023-05-03 16:28:20 2023-02-22 16:39:54 2022-11-09 14:38:31 2022-02-24 17:38:52 2021-02-24 15:34:10
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 157M 452M 705M 134M 225M 119M 788M 144M 188M 131M 587M 160M 810M 729M
costOfRevenue 2M 4M 11M 1M 10M 8M 9M 2M 3M 1 000 000 14M 2M 11M 12M
grossProfit 154M 448M 694M 133M 216M 112M 779M 142M 185M 130M 573M 158M 800M 717M
grossProfitRatio 0.985 0.991 0.992 0.957 0.935 0.986 0.984 0.992 0.988
researchAndDevelopmentExpenses 218M 217M 902M 220M 222M 214M 900M 215M 230M 198M 833M 87M 643M 535M
generalAndAdministrativeExpenses 97M 91M 268M 62M 0 53M 233M 70M 46M 46M 150M 34M 171M 332M
sellingAndMarketingExpenses 0 0 0 0 0 -6M 0 0 -100 000 484 000 -5000 -400 000 0 0
sellingGeneralAndAdministrativeExpenses 97M 91M 268M 62M 60M 47M 233M 70M 46M 46M 150M 34M 171M 332M
otherExpenses 9000 22 000 -26 000 0 610 000 277 000 19 000 20M 32M 17M 147 000 96M 16M 22M
operatingExpenses 315M 308M 1 169M 281M 282M 261M 1 132M 285M 276M 244M 983M 217M 830M 889M
costAndExpenses 317M 312M 1 180M 282M 291M 269M 1 141M 287M 279M 245M 998M 219M 841M 901M
interestIncome 24M 25M 107M 2M 0 49 000 89M 24M 0 0 25M 0 10M 31M
interestExpense 22M 23M 90M 21M 23M 21M 81M 18M 18M 16M 8M 2M 9M 10M
depreciationAndAmortization 5M 5M 22M 24M 6M 6M 22M 20M 6M 17M 22M 14M 20M 17M
ebitda -103M 150M -354M -125M -38M -144M -236M -123M -59M -97M -228M -45M -5M -111M
ebitdaratio -0.659 0.332 -0.933 -0.269 -1.204 -0.854 -0.314 -0.74 -0.278
operatingIncome -160M 140M -475M -149M -66M -150M -354M -143M -91M -114M -410M -59M -30M -172M
operatingIncomeRatio -1.022 0.309 -1.109 -0.293 -1.251 -0.993 -0.484 -0.87 -0.367
totalOtherIncomeExpensesNet 32M -16M 15M 5M -110 000 7M 20M 20M 32M 1 000 000 152M 12M 1M 38M
incomeBeforeTax -128M 124M -460M -144M -66M -143M -334M -141M -77M -113M -258M -47M -29M -135M
incomeBeforeTaxRatio -0.819 0.273 -1.075 -0.294 -1.194 -0.979 -0.41 -0.863 -0.294
incomeTaxExpense 213 000 -20 000 -6M -4M 64 000 75 000 32M 6M 8M 11M 12M 283 000 -551 000 345M
netIncome -129M 124M -454M -140M -66M -143M -366M -147M -85M -124M -270M -47M -29M -444M
netIncomeRatio -0.821 0.273 -1.048 -0.294 -1.195 -1.021 -0.452 -0.947 -0.296
eps -0.8 0.78 -3.04 -0.95 -0.45 -0.98 -2.56 -1.03 -0.59 -0.87 -1.9 -0.33 -0.2 -3.18
epsdiluted -0.8 0.68 -0.95 -0.45 -0.98 -1.03 -0.59 -0.87 -0.33
weightedAverageShsOut 161M 159M 150M 149M 146M 146M 143M 143M 143M 143M 142M 142M 141M 140M
weightedAverageShsOutDil 161M 182M 150M 149M 146M 146M 143M 143M 143M 143M 142M 142M 141M 140M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-21 2023-02-22 2022-02-25 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 17M 8M 17M 695 000 21M
ebit -376M -258M -250M -25M -128M
nonOperatingIncomeExcludingInterest -99M -95M -160M -5M -44M
netIncomeFromContinuingOperations -454M -366M -270M -29M -480M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -454M -366M -270M -29M -444M
epsDiluted -3.04 -2.56 -1.9 -0.2 -3.18

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-10-28 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015
fillingDate 2025-10-28 2025-07-30 2024-11-06 2024-08-01 2024-03-31 2023-11-02 2023-08-09 2023-05-03 2022-11-09
acceptedDate 2025-10-29 03:06:01 2025-07-30 15:56:18 2025-02-19 16:06:39 2024-11-06 16:06:54 2024-08-01 16:57:19 2024-03-29 20:00:00 2024-02-21 16:38:27 2023-11-02 14:43:27 2023-08-09 13:50:14 2023-05-03 16:28:20 2023-02-22 16:39:54 2022-11-09 14:38:31 2022-02-24 17:38:52 2021-02-24 15:34:10
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 338M 297M 242M 335M 294M 349M 399M 352M 425M 309M 276M 1 982M 869M 398M
shortTermInvestments 1 902M 1 993M 2 056M 2 149M 1 785M 1 857M 1 932M 1 884M 1 961M 2 038M 1 721M 1 667M 1 264M 1 495M
cashAndShortTermInvestments 2 240M 2 290M 2 298M 2 483M 2 079M 2 206M 2 331M 2 236M 2 385M 2 347M 1 997M 3 649M 2 133M 1 892M
netReceivables 25M 53M 92M 18M 27M 5M 98M 142M 28M 14M 26M 7M 62M 76M
inventory 10M 8M 13M 28M 29M 30M 7M 26M 26M 22M 22M 21M 25M 22M
otherCurrentAssets 244M 226M 218M 184M 195M 174M 205M 207M 203M 182M 158M -1 687M 125M 140M
totalCurrentAssets 2 519M 2 577M 2 620M 2 714M 2 329M 2 416M 2 642M 2 585M 2 616M 2 543M 2 203M 1 982M 2 345M 2 131M
propertyPlantEquipmentNet 348M 276M 256M 247M 243M 242M 243M 245M 269M 264M 256M 181M 196M 181M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 30M 29M 28M
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 30M 29M 28M
longTermInvestments 52M 23M 41M 0 41M 43M 43M 43M 0 0 40M 0 32M 15M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 114M 109M 86M 120M 78M 63M 62M 61M 86M 78M 35M -30M 9M 35M
totalNonCurrentAssets 514M 408M 383M 367M 362M 348M 348M 349M 355M 342M 331M 181M 267M 259M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 259M 0 0
totalAssets 3 033M 2 985M 3 004M 3 081M 2 691M 2 764M 2 990M 2 934M 2 971M 2 885M 2 534M 2 422M 2 612M 2 390M
accountPayables 14M 23M 43M 9M 9M 13M 26M 6M 24M 10M 18M 21M 12M 17M
shortTermDebt 631M 630M 9M 44M 44M 44M 53M 31M 25M 0 8M 5M 4M 309M
taxPayables 0 81 000 34 000 41 000 284 000 2M 2M 31M 25M 17M 6M 16 000 36 000 1M
deferredRevenue 77M 76M 79M 76M 94M 130M 151M 205M 96M 92M 91M 100M 98M 108M
otherCurrentLiabilities 181M 168M 70M 175M 158M 140M 68M 675M 653M 662M 49M -26M 39M 73M
totalCurrentLiabilities 903M 897M 309M 305M 306M 328M 448M 917M 798M 764M 312M 100M 241M 599M
longTermDebt 859M 790M 1 245M 1 402M 1 933M 1 756M 1 230M 1 404M 1 474M 1 361M 1 183M 1 249M 1 228M 600M
deferredRevenueNonCurrent 108M 125M 157M 0 189M 215M 241M 249M 254M 273M 288M 295M 352M 424M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 -1 727M -356M 0 0 0 -505M 0 0 0 0
otherNonCurrentLiabilities 545M 541M 542M 712M 0 525M 514M 49M 17M 505M 0 1 602M 0 23M
totalNonCurrentLiabilities 1 512M 1 456M 2 106M 2 114M 2 121M 2 140M 2 155M 1 702M 1 745M 1 634M 1 649M 1 728M 1 599M 1 048M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 263M 164M 162M 168M 166M 169M 171M 173M 175M 177M 179M 84M 19M 0
totalLiabilities 2 415M 2 353M 2 415M 2 419M 2 427M 2 467M 2 603M 2 619M 2 543M 2 398M 1 961M 1 828M 1 840M 1 646M
preferredStock 0 0 0 0 2 040M 0 0 0 0 0 0 0 0 0
commonStock 161 000 159 000 158 000 158 000 146 000 146 000 144 000 143 000 143 000 143 000 142 000 142 000 141 000 140 000
retainedEarnings -2 402M -2 273M -2 250M -2 145M -2 005M -1 939M -1 796M -1 787M -1 639M -1 554M -1 430M -1 272M -1 160M -1 131M
accumulatedOtherComprehensiveIncomeLoss -26M -28M -31M -24M -35M -35M -33M -46M -51M -49M -57M -63M -33M -21M
othertotalStockholdersEquity 3 046M 2 933M 2 832M 2 303M 2 270M 2 148M 2 118M 2 090M 1 929M
totalStockholdersEquity 618M 632M 588M 662M 264M 297M 387M 315M 428M 487M 573M 594M 772M 743M
totalEquity 618M 632M 588M 662M 264M 297M 387M 315M 428M 487M 573M 594M 772M 743M
totalLiabilitiesAndStockholdersEquity 3 033M 2 985M 3 081M 2 691M 2 764M 2 934M 2 971M 2 885M 2 422M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 3 033M 2 985M 3 004M 3 081M 2 691M 2 764M 2 990M 2 934M 2 971M 2 885M 2 534M 2 422M 2 612M 2 390M
totalInvestments 1 957M 2 018M 2 102M 2 149M 1 826M 1 900M 1 981M 1 884M 1 961M 2 038M 1 761M 1 667M 1 296M 1 517M
totalDebt 1 489M 1 420M 1 417M 1 447M 1 977M 1 969M 1 454M 1 404M 1 474M 1 361M 1 369M 1 254M 1 251M 909M
netDebt 1 151M 1 123M 1 174M 1 112M 1 683M 1 620M 1 054M 1 052M 1 049M 1 052M 1 093M -728M 382M 511M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-21 2023-02-22 2022-02-25 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 92M 98M 26M 62M 76M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 43M 28M 24M 12M 19M
otherPayables 34 000 2M 6M 36 000 1M
accruedExpenses 108M 148M 140M 89M 90M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 162M 171M 179M 19M 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 869M 2 215M 2 060M 1 964M 1 896M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-10-28 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS IONS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015
fillingDate 2025-10-28 2025-07-30 2024-11-06 2024-08-01 2024-03-31 2023-11-02 2023-08-09 2023-05-03 2022-11-09
acceptedDate 2025-10-29 03:06:01 2025-07-30 15:56:18 2025-02-19 16:06:39 2024-11-06 16:06:54 2024-08-01 16:57:19 2024-03-29 20:00:00 2024-02-21 16:38:27 2023-11-02 14:43:27 2023-08-09 13:50:14 2023-05-03 16:28:20 2023-02-22 16:39:54 2022-11-09 14:38:31 2022-02-24 17:38:52 2021-02-24 15:34:10
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -129M 124M -454M -140M -66M -143M -366M -147M -85M -124M -270M 18M -29M -487M
depreciationAndAmortization 12M 5M 20M 4M 6M 6M 22M 6M 6M 6M 22M 22M 20M 17M
deferredIncomeTax 0 0 0 0 0 0 0 6M -19M 0 0 0 25M 313M
stockBasedCompensation 31M 30M 130M 32M 31M 31M 106M 26M 27M 27M 100M 75M 121M 230M
changeInWorkingCapital 70M -28M -209M 140M -94M -46M -77M -4M -32M -55M 8M -18M -114M -74M
accountsReceivables -40M -13M 6M 9M -22M 93M -72M -94M -41M 0 36M 0 5M -22M
inventory 12M -13M -5M 271 000 2M -2M -6M -96 000 -3M -167 000 3M 4M -3M -1M
accountsPayables 20M 6M 16M -2M -3M -14M 8M -18M 16M -10M 1M 6M -6M -3M
otherWorkingCapital 76M -8M -226M 132M -70M -122M -7M 108M -3M -45M -33M -28M -110M -48M
otherNonCashItems -115M 21M 12M -150M 4M -33M 8M 4M 6M 13M -135M -171M 8M 36M
netCashProvidedByOperatingActivities -131M 151M -501M -115M -120M -150M -308M -109M -97M -134M -274M -74M 31M 36M
investmentsInPropertyPlantAndEquipment -5M -12M -45M 6M -20M -6M -24M -3M -13M -12M -20M 3M -18M -41M
acquisitionsNet 0 0 0 0 0 0 22 000 1M 1M 1M 254M 0 6M 6M
purchasesOfInvestments -324M -492M -1 853M -715M -285M -519M -1 771M -421M -244M -688M -1 486M -1 223M -1 131M -1 570M
salesMaturitiesOfInvestments 422M 386M 1 769M 371M 368M 601M 1 585M 493M 327M 374M 989M 764M 1 344M 1 886M
otherInvestingActivites -2M -2M -3M 0 81M -1M -1M -1M -4M
netCashUsedForInvestingActivites 91M -120M -341M 62M 76M 69M 70M -326M -474M
debtRepayment -41 000 -40 000 -48 000 -39 000 -39 000 -68M -420M -39 000 -89 000
commonStockIssued 81M 1M 496M 3M 24M 4M 2M 3M 3M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 -91M
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 496M 0 24M 32M 561M 490M -7M
netCashUsedProvidedByFinancingActivities 81M 1M 496M 3M 24M -32M 144M 492M -4M
effectOfForexChangesOnCash -82 000 595 000 -273 000 350 000 -23 000 -114 000 352 000 -152 000 70 000 104 000 -418 000 -963 846 -111 000 617 000
netChangeInCash 41M 33M -157M 41M -55M -50M 123M -73M 116M 33M -593M -228M 472M -286M
cashAtEndOfPeriod 338M 297M 242M 335M 294M 349M 399M 352M 425M 309M 276M 315M 869M 398M
cashAtBeginningOfPeriod 297M 264M 399M 294M 349M 399M 276M 425M 309M 276M 869M 543M 398M 683M
operatingCashFlow -131M 151M -501M -115M -120M -150M -308M -109M -97M -134M -274M -74M 31M 36M
capitalExpenditure -3M -14M -45M 6M -20M -6M -28M -3M -13M -12M -20M 3M -18M -41M
freeCashFlow -135M 137M -546M -111M -140M -156M -336M -112M -110M -146M -294M -71M 13M -5M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-21 2023-02-22 2022-02-25 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -5M -4M 0 -6M -6M
netCashProvidedByInvestingActivities -134M -214M -263M 195M 274M
netDebtIssuance -45M 87M -51M 314M 0
longTermNetDebtIssuance -167 000 87M -51M 314M 0
shortTermNetDebtIssuance -45M 0 0 0 0
netStockIssuance 523M 49M 6M 86M -104M
netCommonStockIssuance 523M 49M 6M 86M -39M
commonStockIssuance 523M 49M 6M 86M 52M
netPreferredStockIssuance 0 0 0 0 -65M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 508M -11M -153M -493M
netCashProvidedByFinancingActivities 478M 644M -55M 246M -597M
incomeTaxesPaid 0 48M 5M 38 000 26M
interestPaid 0 7M 3M 5M 6M

Earning call transcript

2025 q3
2025-10-29 ET (fiscal 2025 q3)
2025 q2
2025-07-30 ET (fiscal 2025 q2)
2025 q1
2025-04-30 ET (fiscal 2025 q1)
2024 q4
2025-02-19 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-21 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-09 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-10-29 20:43 ET
Ionis Pharmaceuticals reported for 2025 q3
SEC form 8
2025-10-29 11:06 ET
Ionis Pharmaceuticals published news for 2025 q3
SEC form 8
2025-10-29 11:06 ET
Ionis Pharmaceuticals reported for 2025 q3
SEC form 10
2025-07-30 19:56 ET
Ionis Pharmaceuticals reported for 2025 q2
SEC form 8
2025-07-30 15:16 ET
Ionis Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-30 15:16 ET
Ionis Pharmaceuticals reported for 2025 q2
SEC form 10
2025-04-30 00:00 ET
Ionis Pharmaceuticals reported for 2025 q1
SEC form 8
2025-04-30 00:00 ET
Ionis Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-30 00:00 ET
Ionis Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-19 00:00 ET
Ionis Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Ionis Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Ionis Pharmaceuticals reported for 2024 q4
SEC form 10
2024-11-06 16:06 ET
Ionis Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-06 11:15 ET
Ionis Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-06 11:15 ET
Ionis Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-01 16:57 ET
Ionis Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-01 11:15 ET
Ionis Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-01 11:15 ET
Ionis Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Ionis Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-07 15:55 ET
Ionis Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-07 11:15 ET
Ionis Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-07 11:15 ET
Ionis Pharmaceuticals reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Ionis Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-21 16:38 ET
Ionis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-21 11:17 ET
Ionis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-21 11:17 ET
Ionis Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-21 00:00 ET
Ionis Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-02 14:43 ET
Ionis Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-02 11:15 ET
Ionis Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Ionis Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-09 13:50 ET
Ionis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-09 11:15 ET
Ionis Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Ionis Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Ionis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-04 16:30 ET
Ionis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-03 16:30 ET
Ionis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-10 07:00 ET
Ionis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-12 16:03 ET
Ionis Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-06 16:12 ET
Ionis Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-05 10:56 ET
Ionis Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Ionis Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Ionis Pharmaceuticals reported for 2023 q1
SEC form 6
2023-03-27 06:01 ET
Ionis Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-22 16:39 ET
Ionis Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-22 11:15 ET
Ionis Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-22 00:00 ET
Ionis Pharmaceuticals reported for 2022 q4
SEC form 8
2023-02-22 00:00 ET
Ionis Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-09 09:10 ET
Ionis Pharmaceuticals published news for 2022 q4
SEC form 6
2022-11-14 06:10 ET
Ionis Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-09 14:38 ET
Ionis Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-09 11:15 ET
Ionis Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Ionis Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-09 00:00 ET
Ionis Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-04 07:05 ET
Ionis Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-24 10:00 ET
Ionis Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-12 07:15 ET
Ionis Pharmaceuticals published news for 2022 q3
SEC form 10
2022-08-09 15:56 ET
Ionis Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-09 11:15 ET
Ionis Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Ionis Pharmaceuticals reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Ionis Pharmaceuticals reported for 2022 q2
SEC form 6
2022-07-28 06:02 ET
Ionis Pharmaceuticals published news for 2022 q2
SEC form 6
2022-07-19 06:02 ET
Ionis Pharmaceuticals published news for 2022 q2
SEC form 6
2022-07-15 20:16 ET
Ionis Pharmaceuticals published news for 2022 q2
SEC form 6
2022-07-11 10:14 ET
Ionis Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-21 06:03 ET
Ionis Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-06 16:00 ET
Ionis Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-04 17:11 ET
Ionis Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-04 11:15 ET
Ionis Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Ionis Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Ionis Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-20 12:22 ET
Ionis Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-18 18:03 ET
Ionis Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-25 00:00 ET
Ionis Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-24 17:38 ET
Ionis Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 11:15 ET
Ionis Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Ionis Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-31 07:32 ET
Ionis Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-07 06:02 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-26 16:05 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-24 09:29 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-03 15:37 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-03 11:15 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-18 14:31 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-04 15:20 ET
Ionis Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-04 11:15 ET
Ionis Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Ionis Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Ionis Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-04 16:43 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-05 14:58 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-05 11:16 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-23 06:08 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-12 21:13 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-06 07:00 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-29 10:23 ET
Ionis Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-22 19:40 ET
Ionis Pharmaceuticals published news for 2020 q4
SEC form 10
2021-02-24 15:34 ET
Ionis Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-24 08:45 ET
Ionis Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-17 21:21 ET
Ionis Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-09 06:13 ET
Ionis Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-04 17:01 ET
Ionis Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-04 11:15 ET
Ionis Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-13 08:43 ET
Ionis Pharmaceuticals published news for 2020 q3